Nutcracker Therapeutics
As the Chief Operating Officer at Nutcracker Therapeutics, Madhu Balachandran leads all aspects of the company’s operations, including manufacturing, quality, and product development functions. Previously, he had roles of increasing responsibility over a 20-year career at Amgen, Inc., ending as Executive Vice President, Operations. Prior to his tenure at Amgen, Madhu held leadership positions at Copley Pharmaceuticals, now a part of Teva Pharmaceuticals Industries Ltd., and Burroughs Wellcome, now part of GlaxoSmithKline plc. In addition he serves as a director of Stevanato Group, Catalent, Inc., uniQure NV, and A2 Biotherapeutics.
This person is not in any offices
Nutcracker Therapeutics
Nutcracker Therapeutics is an early-stage biotech disrupter founded to develop mRNA-based therapeutic drug products which will be manufactured on the novel ACORN (Automation COntroled RNA) microfluidic-based manufacturing system.